We serve Chemical Name:N,N-Dimethyl-6-indolinamine CAS:214614-94-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N,N-Dimethyl-6-indolinamine
CAS.NO:214614-94-5
Synonyms:N,N-Dimethyl-6-indolinamine
Molecular Formula:C10H14N2
Molecular Weight:162.23200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:15.27000
Exact Mass:162.11600
LogP:1.85860
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N,N-Dimethyl-6-indolinamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-Dimethyl-6-indolinamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N-Dimethyl-6-indolinamine Use and application,N,N-Dimethyl-6-indolinamine technical grade,usp/ep/jp grade.
Related News: ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. N,N-Dimethyl-6-indolinamine manufacturer ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. N,N-Dimethyl-6-indolinamine supplier ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. N,N-Dimethyl-6-indolinamine vendor With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand. N,N-Dimethyl-6-indolinamine factory With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.
